OKYO Pharma Limited

TickerCurrent Price% Daily ChangeVolume (1,000s)Average Volumn (1,000s)Market Cap (Millions)1/2/2024 Price% Change Since Inception 1/2/2024

Contact Information

OKYO Pharma Limited
Head Office – USA
420 Lexington Avenue
Suite 1402
New York, NY 10170

OKYO Pharma focuses on:
A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis.
An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.